Home > Healthcare

COVID-19 remains a priority for govt

(chinadaily.com.cn)

While the end of the COVID-19 pandemic seems in sight, experts and officials said on Saturday that vaccinating vulnerable groups against the disease, monitoring immunity levels across its population and stepping up preparedness for developing novel and variant-specific vaccines will remain essential tasks.

Qi Xiaopeng, a researcher at the Chinese Center for Disease Control and Prevention, said that the numbers of new infections and related deaths globally have both dropped to lowest levels since the virus first emerged in late 2019, citing data from the World Health Organization.

Around 50 countries, mostly in Africa and North America, have reported no new infections in the past 30 days. Many other countries have also reduced the frequency of COVID-19 cases with the epidemic waning, she said during an event held during the 2023 National Vaccines and Health Conference.

The event, the fifth of its kind, was jointly held by the Chinese Preventive Medicine Association and the China CDC in Hangzhou, Zhejiang province, from Saturday to Sunday.

China downgraded management of the disease from Class A to B on Jan 8. Qi said that as of April 11, 192 countries and region no longer required negative nucleic acid testing from vaccinated incoming passengers from the Chinese mainland.

Li Bin, vice-minister of the National Health Commission, said that China's mass vaccination campaign has played a vital role in enabling the country to protect susceptible groups, reducing severe cases and deaths and securing a victory against the disease.

As of recently, the mainland had delivered nearly 3.5 billion doses and fully vaccinated about 1.28 billion people, according to official data.

"At present and for quite some time in the future, it is important to step up research on immunogenicity, length and strength of long-term immunity of COVID-19 vaccines, as well as closely studying new variants' impact on existing vaccines, and beefing up vaccine development preparedness against key novel strains," he said.

So far, China has 17 COVID-19 vaccine products that have completed or are undergoing third-stage human trials.

Yin Zundong, head of the China CDC's national immunization program, said that developing and promoting vaccines tailored to target new variants or capable of tackling multiple variants are bound to be a priority task in the future.

He added that with the highly-transmissible Omicron and its offshoots in circulation, heightened efforts will be dedicated into expanding coverage among the elderly and vulnerable groups, such as those with chronic diseases, who are at higher risk of developing severe cases and deaths after infection.

Yin added that researchers are pushing research into evaluating real-world efficacy outcomes of domestic COVID-19 vaccines.

8.03K
Videos
 
6535e360a3109068cafea54b.jpeg

Images: 2023 World Internet of Things Exposition

The Xiangfu Temp 副本.JPG

In pics: Visitors brave the rain to admire grand Buddha

news.jpg

Calligraphy and painting exhibition opens at Wuxi Museum

640 - 副本.png

Rice paddy designs captivate in Wuxi

News
Sports
Videos
Photos
Business
Biz Updates
Industries
Development Zones
Companies
Travel
Attractions
Dining
Accommodation
Shopping
Entertainment
Transportation
Maps
Culture
Culture News
Heritage
Museums
Events
Services
Visa
Marriage
Healthcare
Jobs
Education
Useful Info
Government
Mayor
Departments
Districts
Policies
About
Overview
Statistics
Sister Cities
E-books
Copyright © China Daily. All rights reserved.
The Information Office of Wuxi Municipal People's Government.
Presented by China Daily.
备案号:京ICP备13028878号-34